Ladder Therapeutics is a Y Combinator-backed company, working at the intersection of machine learning and RNA biology. We are creating an in-silico and in-vitro platform that enables the discovery of small molecule modulators of RNA. We are backed by mission driven investors - Hummingbird Ventures and 50Years.

The current toolkit for developing drugs is focused almost entirely on the protein targets. The actions of these proteins however are known to be influenced by areas of the genome that do not encode proteins, the non-coding genome, classically termed “junk DNA”. Variation in the non-coding genome, the “dark genome” is associated with many diseases but remains inaccessible by classical drug discovery. We are building a company at the intersection of machine learning, novel chemistry and RNA biology to shine light on the dark genome. We are curious, nimble, breaking new ground and growing fast. Come make an impact with us and be part of our story.